Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 78889, held by Reddys. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 78889 (Metoprolol Succinate), held by Reddys, was first approved by FDA on Aug 15, 2012, with 5 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets are a beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 15, 2012 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| May 26, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 26, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 15, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 27, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 27, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 15, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters